Cover Image
Market Research Report
Product code 
1110932

NA Cardiac Safety Services Market - Industry Trends and Forecast to 2029

Published: | Data Bridge Market Research Private Limited | 151 Pages | Delivery time: Inquiry

Price

Back to Top
NA Cardiac Safety Services Market - Industry Trends and Forecast to 2029
Published: April 1, 2022
Data Bridge Market Research Private Limited
Content info: 151 Pages
Delivery time: Inquiry
  • Description
  • Table of Contents
  • List of Tables

North America cardiac safety services market is projected to register a CAGR of 15.7% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.

Market Segmentation:

North America Cardiac Safety Services Market, By Services (ECG/Holter Measurements, Blood Pressure Measurements, In Vitro Cardiac Safety Assessment Services, Cardiovascular Imaging, Real-Time Telemetry Monitoring, Central Over-Read of ECGS, Non-Invasive Cardiac Imaging, Physiologic Stress Testing, Thorough QT Studies, TQT and Exposure Response Modeling, Platelet Aggregation and Other Services), Phase (Phase 1, Phase 2 and Phase 3), Type (Integrated Services and Standalone Services), End User (Pharmaceuticals & Biopharmaceuticals Companies, Contract Research Organizations and Academic and Research Institute) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the North America cardiac safety services market are:

Growing awareness among people regarding cardiac problems and chronic heart disease

increasing research and development expenditure by the healthcare industries

Market Players:

The key market players for North America cardiac safety services market are listed below:

Koninklijke Philips N.V.

Laboratory Corporation of America Holdings

IQVIA

Medpace

Ncardia

Certara

Eurofins Scientific

SGS SA

Banook

Celerion

PhysioStim

Shanghai Medicilon Inc

Clario

PPD Inc

TABLE OF CONTENTS

1 INTRODUCTION 26

  • 1.1 OBJECTIVES OF THE STUDY 26
  • 1.2 MARKET DEFINITION 26
  • 1.3 OVERVIEW OF NORTH AMERICA CARDIAC SAFETY SERVICES MARKET 26
  • 1.4 LIMITATIONS 27
  • 1.5 MARKETS COVERED 28

2 MARKET SEGMENTATION 30

  • 2.1 MARKETS COVERED 30
  • 2.2 GEOGRAPHICAL SCOPE 31
  • 2.3 YEARS CONSIDERED FOR THE STUDY 32
  • 2.4 CURRENCY AND PRICING 32
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 33
  • 2.6 MULTIVARIATE MODELLING 36
  • 2.7 SERVICES LIFELINE CURVE 36
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37
  • 2.9 DBMR MARKET POSITION GRID 38
  • 2.10 MARKET END USER GRID 40
  • 2.11 VENDOR SHARE ANALYSIS 41
  • 2.12 SECONDARY SOURCES 42
  • 2.13 ASSUMPTIONS 42

3 EXECUTIVE SUMMARY 43

4 PREMIUM INSIGHTS 46

  • 4.1 PORTERS FIVE FORCES 47
  • 4.2 PESTEL ANALYSIS 48

5 EPIDEMIOLOGY 49

  • 5.1 INCIDENCE OF ALL BY GENDER 49
  • 5.2 TREATMENT RATE 50
  • 5.3 MORTALITY RATE 50
  • 5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 51

6 INDUSTRY INSIGHT 52

  • 6.1 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 52
  • 6.2 PATENT ANALYSIS 53
  • 6.3 PATENT FLOW DIAGRAM 54
  • 6.4 KEY PATIENT ENROLLMENT STRATEGIES 54
  • 6.5 PRICING STRATEGY 57

7 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: REGULATIONS 58

8 MARKET OVERVIEW 61

  • 8.1 DRIVERS 63
    • 8.1.1 INCREASE IN THE NUMBER OF CLINICAL TRIALS 63
    • 8.1.2 INCREASE IN HEALTHCARE EXPENDITURE AND FUNDING 63
    • 8.1.3 INCREASE IN STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 64
    • 8.1.4 INCREASE IN R&D ACTIVITIES 64
  • 8.2 RESTRAINTS 65
    • 8.2.1 HIGH COST OF CARDIAC SAFETY EVALUATION 65
    • 8.2.2 STRICT REGULATORY 65
  • 8.3 OPPORTUNITIES: 66
    • 8.3.1 INCREASE IN NEW DRUG DEVELOPMENT 66
    • 8.3.2 RISE IN THE EXPANSION OF THE CARDIAC SAFETY SERVICES 67
  • 8.4 CHALLENGES 67
    • 8.4.1 TIME-CONSUMING PROCEDURE 67
    • 8.4.2 LACK OF SKILLED PERSON TO OPERATE DEVICES DURING CARDIAC SAFETY EVALUATION 68

9 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES 69

  • 9.1 OVERVIEW 70
  • 9.2 ECG/HOLTER MEASUREMENTS 74
  • 9.3 BLOOD PRESSURE MEASUREMENTS 74
  • 9.4 IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES 75
    • 9.4.1 HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS 76
      • 9.4.1.1 1 CONCENTRATIONS 76
      • 9.4.1.2 4 CONCENTRATIONS 76
    • 9.4.2 COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) 77
      • 9.4.2.1 3 CONCENTRATIONS 77
      • 9.4.2.2 5 CONCENTRATIONS 77
    • 9.4.3 IN VITRO HERG ASSAY 77
    • 9.4.4 OTHERS 77
  • 9.5 CARDIOVASCULAR IMAGING 77
  • 9.6 REAL TIME TELEMETRY MONITORING 78
  • 9.7 CENTRAL OVER-READ OF ECGS 79
  • 9.8 NON-INVASIVE CARDIAC IMAGING 79
  • 9.9 PHYSIOLOGIC STRESS TESTING 80
  • 9.10 THOROUGH QT STUDIES 81
  • 9.11 TQT AND EXPOSURE RESPONSE MODELLING 81
  • 9.12 PLATELET AGGREGATION 82
  • 9.13 OTHERS 83

10 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY PHASE 84

  • 10.1 OVERVIEW 85
  • 10.2 PHASE I 88
  • 10.3 PHASE II 88
  • 10.4 PHASE III 89

11 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY TYPE 90

  • 11.1 OVERVIEW 91
  • 11.2 INTEGRATED SERVICES 94
  • 11.3 STANDALONE SERVICES 95

12 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY END USER 96

  • 12.1 OVERVIEW 97
  • 12.2 PHARMACEUTICALS & BIOPHARMACEUTICALS COMPANIES 100
  • 12.3 CONTRACT RESEARCH ORGANIZATIONS 100
  • 12.4 ACADEMIC AND RESEARCH INSTITUTE 101

13 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY REGION 102

  • 13.1 NORTH AMERICA 103
    • 13.1.1 U.S. 111
    • 13.1.2 CANADA 114
    • 13.1.3 MEXICO 117

14 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: COMPANY LANDSCAPE 120

  • 14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 120

15 COMPANY PROFILE 121

  • 15.1 EUROFINS SCIENTIFIC 121
    • 15.1.1 COMPANY SNAPSHOT 121
    • 15.1.2 REVENUE ANALYSIS 122
    • 15.1.3 COMPANY SHARE ANALYSIS 122
    • 15.1.4 PRODUCT PORTFOLIO 122
    • 15.1.5 RECENT DEVELOPMENTS 123
      • 15.1.5.1 AGREEMENTS 123
      • 15.1.5.2 ACQUISITION 123
  • 15.2 PPD INC. (SUBSIDIARY OF THERMO FISHER SCIENTIFIC INC) 124
    • 15.2.1 COMPANY SNAPSHOT 124
    • 15.2.2 REVENUE ANALYSIS 124
    • 15.2.3 COMPANY SHARE ANALYSIS 125
    • 15.2.4 PRODUCT PORTFOLIO 125
    • 15.2.5 RECENT DEVELOPMENT 125
      • 15.2.5.1 INVESTMENT 125
  • 15.3 KONINKLIJKE PHILIPS N.V. 126
    • 15.3.1 COMPANY SNAPSHOT 126
    • 15.3.2 REVENUE ANALYSIS 126
    • 15.3.3 COMPANY SHARE ANALYSIS 127
    • 15.3.4 PRODUCT PORTFOLIO 127
    • 15.3.5 RECENT DEVELOPMENT 127
      • 15.3.5.1 ACQUISITION 127
  • 15.4 IQVIA 128
    • 15.4.1 COMPANY SNAPSHOT 128
    • 15.4.2 REVENUE ANALYSIS 128
    • 15.4.3 COMPANY SHARE ANALYSIS 129
    • 15.4.4 PRODUCT PORTFOLIO 129
    • 15.4.5 RECENT DEVELOPMENTS 129
      • 15.4.5.1 ACQUISITION 129
  • 15.5 LABORATORY CORPORATION OF AMERICA HOLDINGS 130
    • 15.5.1 COMPANY SNAPSHOT 130
    • 15.5.2 REVENUE ANALYSIS 130
    • 15.5.3 COMPANY SHARE ANALYSIS 131
    • 15.5.4 PRODUCT PORTFOLIO 131
    • 15.5.5 RECENT DEVELOPMENTS 131
      • 15.5.5.1 NEW LABORATORY 131
      • 15.5.5.2 ACQUISITION 131
  • 15.6 BANOOK 132
    • 15.6.1 COMPANY SNAPSHOT 132
    • 15.6.2 PRODUCT PORTFOLIO 132
    • 15.6.3 RECENT DEVELOPMENT 132
      • 15.6.3.1 AGREEMENT 132
  • 15.7 BIOTRIAL 133
    • 15.7.1 COMPANY SNAPSHOT 133
    • 15.7.2 PRODUCT PORTFOLIO 133
    • 15.7.3 RECENT DEVELOPMENT 133
      • 15.7.3.1 NEW CENTER OPENING 133
  • 15.8 CELERION 134
    • 15.8.1 COMPANY SNAPSHOT 134
    • 15.8.2 PRODUCT PORTFOLIO 134
    • 15.8.3 RECENT DEVELOPMENT 134
      • 15.8.3.1 NEW CENTER OPENING 134
  • 15.9 CERTARA 135
    • 15.9.1 COMPANY SNAPSHOT 135
    • 15.9.2 REVENUE ANALYSIS 135
    • 15.9.3 PRODUCT PORTFOLIO 136
    • 15.9.4 RECENT DEVELOPMENTS 136
      • 15.9.4.1 CONTRACT 136
      • 15.9.4.2 ACQUISITION 136
  • 15.10 CLARIO 137
    • 15.10.1 COMPANY SNAPSHOT 137
    • 15.10.2 PRODUCT PORTFOLIO 137
    • 15.10.3 RECENT DEVELOPMENT 137
      • 15.10.3.1 PRODUCT EXPANSION 137
  • 15.11 MEDPACE 138
    • 15.11.1 COMPANY SNAPSHOT 138
    • 15.11.2 REVENUE ANALYSIS 138
    • 15.11.3 PRODUCT PORTFOLIO 139
    • 15.11.4 RECENT DEVELOPMENTS 139
      • 15.11.4.1 ACQUISITION 139
  • 15.12 NCARDIA 140
    • 15.12.1 COMPANY SNAPSHOT 140
    • 15.12.2 PRODUCT PORTFOLIO 140
    • 15.12.3 RECENT DEVELOPMENT 140
      • 15.12.3.1 PARTNERSHIP 140
  • 15.13 NEXEL CO., LTD 141
    • 15.13.1 COMPANY SNAPSHOT 141
    • 15.13.2 PRODUCT PORTFOLIO 141
    • 15.13.3 RECENT DEVELOPMENTS 141
      • 15.13.3.1 JOINT VENTURE 141
      • 15.13.3.2 PARTNERSHIP 142
  • 15.14 PHYSIOSTIM 143
    • 15.14.1 COMPANY SNAPSHOT 143
    • 15.14.2 PRODUCT PORTFOLIO 143
    • 15.14.3 RECENT DEVELOPMENT 143
      • 15.14.3.1 PARTNERSHIP 143
  • 15.15 RICHMOND PHARMACOLOGY 144
    • 15.15.1 COMPANY SNAPSHOT 144
    • 15.15.2 PRODUCT PORTFOLIO 144
    • 15.15.3 RECENT DEVELOPMENT 144
      • 15.15.3.1 EVENT 144
  • 15.16 SGS SA 145
    • 15.16.1 COMPANY SNAPSHOT 145
    • 15.16.2 REVENUE ANALYSIS 145
    • 15.16.3 PRODUCT PORTFOLIO 146
    • 15.16.4 RECENT DEVELOPMENT 146
      • 15.16.4.1 ACQUISITION 146
  • 15.17 SHANGHAI MEDICILON INC. 147
    • 15.17.1 COMPANY SNAPSHOT 147
    • 15.17.2 PRODUCT PORTFOLIO 147
    • 15.17.3 RECENT DEVELOPMENTS 147
      • 15.17.3.1 PARTNERSHIP 147
      • 15.17.3.2 PARTNERSHIP 148

16 QUESTIONNAIRE 149

17 RELATED REPORTS 151

LIST OF TABLES

  • TABLE 1 PROPORTION OF WOMEN IN CLINICAL STUDIES, ACCORDING TO DEVELOPMENT PHASE 38
  • TABLE 2 PROBABILITY OF SUCCESS BY CLINICAL TRIAL PHASE TO THERAPEUTIC AREA 39
  • TABLE 3 MORTALITY RATES FROM CLINICAL TRIALS AND EUROPEAN SAFETY AND EXPOSURE SURVEY (ESES), DEATHS PER 100 (PYE) 39
  • TABLE 4 ADHERENCE RATE TO COMMON CARDIOVASCULAR MEDICATION 40
  • TABLE 5 PROPORTION OF WOMEN IN CLINICAL STUDIES, ACCORDING TO DEVELOPMENT PHASE 42
  • TABLE 6 INITIATIVES TO INCREASE ENROLLMENT IN CLINICAL TRIALS AMONG UNDERREPRESENTED POPULATIONS 44
  • TABLE 7 ESTIMATED COST OF CARDIAC SAFETY EVALUATION DEVICES 46
  • TABLE 8 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 62
  • TABLE 9 NORTH AMERICA ECG/HOLTER MEASUREMENTS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 63
  • TABLE 10 NORTH AMERICA BLOOD PRESSURE MEASUREMENTS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 64
  • TABLE 11 NORTH AMERICA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 64
  • TABLE 12 NORTH AMERICA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 65
  • TABLE 13 NORTH AMERICA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 65
  • TABLE 14 NORTH AMERICA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 66
  • TABLE 15 NORTH AMERICA CARDIOVASCULAR IMAGING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 67
  • TABLE 16 NORTH AMERICA REAL TIME TELEMETRY MONITORING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 67
  • TABLE 17 NORTH AMERICA CENTRAL OVER-READ OF ECGS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 68
  • TABLE 18 NORTH AMERICA NON-INVASIVE CARDIAC IMAGING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 69
  • TABLE 19 NORTH AMERICA PHYSIOLOGIC STRESS TESTING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 69
  • TABLE 20 NORTH AMERICA THOROUGH QT STUDIES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 70
  • TABLE 21 NORTH AMERICA TQT AND EXPOSURE RESPONSE MODELLING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 71
  • TABLE 22 NORTH AMERICA PLATELET AGGREGATION IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 71
  • TABLE 23 NORTH AMERICA OTHERS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 72
  • TABLE 24 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 76
  • TABLE 25 NORTH AMERICA PHASE I IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 77
  • TABLE 26 NORTH AMERICA PHASE II IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 78
  • TABLE 27 NORTH AMERICA PHASE III IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 78
  • TABLE 28 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 82
  • TABLE 29 NORTH AMERICA INTEGRATED SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 83
  • TABLE 30 NORTH AMERICA STANDALONE SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 84
  • TABLE 31 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 88
  • TABLE 32 NORTH AMERICA PHARMACEUTICALS & BIOPHARMACEUTICALS COMPANIES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 89
  • TABLE 33 NORTH AMERICA CONTRACT RESEARCH ORGANIZATIONS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 90
  • TABLE 34 NORTH AMERICA ACADEMIC AND RESEARCH INSTITUTE IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 90
  • TABLE 35 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 97
  • TABLE 36 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 97
  • TABLE 37 NORTH AMERICA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 97
  • TABLE 38 NORTH AMERICA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 98
  • TABLE 39 NORTH AMERICA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 98
  • TABLE 40 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 98
  • TABLE 41 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 98
  • TABLE 42 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 99
  • TABLE 43 U.S. CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 100
  • TABLE 44 U.S. IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 100
  • TABLE 45 U.S. HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 101
  • TABLE 46 U.S. COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 101
  • TABLE 47 U.S. CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 101
  • TABLE 48 U.S. CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 101
  • TABLE 49 U.S. CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 102
  • TABLE 50 CANADA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 103
  • TABLE 51 CANADA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 103
  • TABLE 52 CANADA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 104
  • TABLE 53 CANADA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 104
  • TABLE 54 CANADA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 104
  • TABLE 55 CANADA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 104
  • TABLE 56 CANADA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 105
  • TABLE 57 MEXICO CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 106
  • TABLE 58 MEXICO IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 106
  • TABLE 59 MEXICO HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 107
  • TABLE 60 MEXICO COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 107
  • TABLE 61 MEXICO CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 107
  • TABLE 62 MEXICO CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 107
  • TABLE 63 MEXICO CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 108

LIST OF FIGURES

  • FIGURE 1 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: SEGMENTATION 18
  • FIGURE 2 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: DATA TRIANGULATION 21
  • FIGURE 3 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: DROC ANALYSIS 22
  • FIGURE 4 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: NORTH AMERICA VS COUNTRY MARKET ANALYSIS 23
  • FIGURE 5 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: COMPANY RESEARCH ANALYSIS 23
  • FIGURE 6 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: INTERVIEW DEMOGRAPHICS 25
  • FIGURE 7 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: DBMR MARKET POSITION GRID 26
  • FIGURE 8 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: MARKET END USER GRID 28
  • FIGURE 9 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: VENDOR SHARE ANALYSIS 29
  • FIGURE 10 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: SEGMENTATION 33
  • FIGURE 11 THE INCREASE IN DEMAND FOR CARDIAC SAFETY SERVICES ARE EXPECTED TO DRIVE THE NORTH AMERICA CARDIAC SAFETY SERVICES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 34
  • FIGURE 12 ECG/HOLTER MEASUREMENTS SUBSTITUTE IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA CARDIAC SAFETY SERVICES MARKET IN 2022 & 2029 34
  • FIGURE 13 PATIENT FLOW DIAGRAM FOR ANY RANDOM DRUG 42
  • FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA CARDIAC SAFETY SERVICES MARKET 50
  • FIGURE 15 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY SERVICES, 2021 58
  • FIGURE 16 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY SERVICES, 2022-2029 (USD MILLION) 59
  • FIGURE 17 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY SERVICES, CAGR (2022-2029) 60
  • FIGURE 18 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY SERVICES, LIFELINE CURVE 61
  • FIGURE 19 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY PHASE, 2021 73
  • FIGURE 20 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY PHASE, 2022-2029 (USD MILLION) 74
  • FIGURE 21 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY PHASE, CAGR (2022-2029) 74
  • FIGURE 22 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY PHASE, LIFELINE CURVE 75
  • FIGURE 23 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY TYPE, 2021 79
  • FIGURE 24 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY TYPE, 2022-2029 (USD MILLION) 80
  • FIGURE 25 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY TYPE, CAGR (2022-2029) 80
  • FIGURE 26 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY TYPE, LIFELINE CURVE 81
  • FIGURE 27 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY END USER, 2021 85
  • FIGURE 28 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY END USER, 2022-2029 (USD MILLION) 86
  • FIGURE 29 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY END USER, CAGR (2022-2029) 86
  • FIGURE 30 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY END USER, LIFELINE CURVE 87
  • FIGURE 31 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: SNAPSHOT (2021) 92
  • FIGURE 32 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021) 93
  • FIGURE 33 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2022 & 2029) 93
  • FIGURE 34 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021 & 2029) 94
  • FIGURE 35 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY SERVICES (2022-2029) 95
  • FIGURE 36 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: COMPANY SHARE 2021 (%) 108